拉米夫定联合干扰素序贯治疗慢性乙型肝炎疗效分析

目的探讨拉米夫定联合干扰素序贯治疗慢性乙型肝炎临床疗效。方法100例慢性乙型肝炎患者随机分为联合组（拉米夫定联合干扰素）和拉米夫定组，每组各40例。结果HBVDNA阴转率两组均为100％；HBeAg血清转换率联合组为82％、拉米夫定组为44％；HBeAg阴转率联合组为84％、拉米夫定组为42％；ALT复常率联合组为100％、拉米夫定组为94％。结论拉米夫定联合干扰素的治疗可诱导包括抗-HB，血清学转换的持续应答，能迅速控制病毒血症，降低拉米夫定的耐药性的发生，有效改善患者肝功能，提高临床疗效，值得临床推广。

Analysis of lamivudine,interferon sequential therapy for treatment of chronic hepatitis B

Objective To investigate the clinical efficacy of lamivudine and interferon sequential therapy for treatment of chronic hepatitis B. Methods 100 cases of patients with chronic hepatitis B were randomly divided into combined group （combination of lamivudine and interferon and lamivudine group）, each group had 40 eases. Results Negative rate of HBVDNA in two groups was 100%; HBeAg seroconversion rate was 82% in the combination group, lamivudine group was 44%; the negative rate of HBeAg was 84% in the combination group, larnivudine group was 42%; the recovery rate of ALT was 100% in the combination group, lamivudine group 94%. Conclusion Treatment of laraivudine combined with interferon can induce anti -HB seroconversion, sustained response, can quickly control viremia, reduce the occurrence of lamivudine resistance, effectively improve the liver function of patients, improve the curative effect, so it is worth the clinical promotion.